Impact of ND0612 on Levodopa-Induced Dyskinesia in Parkinson’s Disease: Post hoc Analyses From a Randomized, Active-Controlled Study
Objective: To evaluate dyskinesia-related outcomes between optimized subcutaneously administered levodopa/carbidopa (ND0612) + immediate-release levodopa/carbidopa (IR-LD/CD) vs optimized oral IR-LD/CD in patients with Parkinson’s disease (PD).…Safety and tolerability of overnight switching from Eetacapone to Opicapone in fluctuating Parkinson’s disease: An open-label preliminary trial in Koreans
Objective: Objectives: 1. Efficacy - Opicapone 50mg qd. to determine effectiveness of optimal dose for switching. 2. Tolerability and safety - compare symptoms and adverse…Longitudinal Remote Monitoring with Wearable Technology in Parkinson Disease: Initiation of A Dyskinesia Insight Network Observational Study
Objective: Evaluate the utility of wearable digital health technology for identifying and characterizing levodopa-induced dyskinesia in real-world settings. Background: Patients with Parkinson disease (PwP) frequently…The Unique Clinical Profile of Dystonia in Parkinson Disease
Objective: Characterize clinical features of dystonia and levodopa-related dyskinesias in Parkinson disease (PD). Background: Dystonia affects 30-60% of individuals with PD. [1] Despite recognition as…Heat Map Visualization of Improved Best ON Time in People With Parkinson’s Disease Treated With Foscarbidopa/Foslevodopa
Objective: Assess the impact of foscarbidopa/foslevodopa (CDp/LDp) continuous subcutaneous infusion (CSCI) on the motor states of people with Parkinson’s disease (PD) across 24 hours via…Increase eye blink rate as a motor fluctuation in levodopa-Induced dyskinesia in parkinson’s disease a forgotten indicator of motor fluctuations a case report
Objective: To recognize the increase eye blink rate (EBR) as a potential motor fluctuation (MF) in a PD patient undergoing levodopa treatment Background: A normal…Reduced Falls With ND0612: Supportive Analyses From the BouNDless Phase 3 Study
Objective: Explore potential reasons for the lower rates of falls with ND0612 vs immediate-release levodopa/carbidopa (IR-LD/CD) therapy reported in the BouNDless study. Background: Falls are…Efficacy of Rifaximin as an Adjunct Treatment for Levodopa induced dyskinesia: Preliminary Results
Objective: To evaluate the efficacy of rifaximin as an adjunct treatment for LID (levodopa induced dyskinesia) in patients with PD through a randomized, double-blind, placebo-controlled…Efficacy of ND0612 in Patients at Different Stages of Disease Severity: Subgroup-Analyses From a Randomized, Active-Controlled Study in People With Parkinson’s Disease Experiencing Motor Fluctuations
Objective: To evaluate the efficacy of investigational ND0612 in reducing motor fluctuations in patients with Parkinson’s disease (PD) at different stages of disease and/or symptom…The effect of vortioxetine and mirtazapine on levodopa-induced dyskinesia in a rat model of Parkinson’s disease
Objective: To investigate the effect of vortioxetine and mirtazapine on levodopa-induced dyskinesia (LID) in a rat model of Parkinson’s disease (PD), we analyzed abnormal involuntary movements (AIMs)…
- 1
- 2
- 3
- …
- 44
- Next Page »